biopharmaceut
also
known
biolog
biolog
differ
pharmaceut
product
small
molecul
creat
use
biolog
process
rather
chemic
synthes
includ
wide
varieti
medicin
product
vaccin
blood
blood
compon
somat
cell
gene
therapi
tissu
recombin
introduct
part
nhpspecif
aspect
standard
toxicolog
studi
season
variat
data
gener
marmoset
howev
interpret
translat
human
question
one
speci
may
also
predict
anoth
specif
safeti
concern
human
addit
substrain
given
speci
differ
geograph
origin
may
also
present
genet
differ
may
consider
impact
outcom
biopharmaceut
evalu
therefor
select
nhp
speci
research
nonclin
develop
requir
care
evalu
numer
ethic
scientif
consider
possibl
use
clinic
candid
alway
advantag
confid
similar
target
distribut
densiti
downstream
signal
physiolog
import
nevertheless
hazard
identif
also
taken
consider
respect
nhp
alway
superior
speci
perhap
limit
number
individu
alloc
nonclin
studi
purpos
chapter
help
reader
understand
best
select
right
nhp
speci
strain
illustr
exampl
sever
nhp
speci
use
research
drug
develop
mani
research
area
close
evolutionari
relationship
human
recent
develop
genom
resourc
also
boost
valu
model
organ
old
world
primat
rhesu
macaqu
macaca
mulatta
cynomolgu
macaqu
macaca
fasciculari
far
commonli
use
speci
new
world
primat
marmoset
callithrix
jacchu
evolutionari
diverg
human
old
world
monkey
sometim
use
two
speci
pharmacolog
relev
biopharmaceut
specif
model
exist
marmoset
three
speci
present
advantag
disadvantag
pharmacolog
toxicolog
assess
biopharmaceut
review
chapter
rel
easi
mainten
captiv
wide
avail
anatom
physiolog
proxim
human
rhesu
macaqu
use
extens
medic
biolog
research
human
anim
healthrel
topic
given
name
rhesu
factor
one
element
human
blood
group
rhesu
macaqu
wide
use
nhp
model
studi
infect
immun
close
genet
relationship
human
averag
humanmacaqu
sequenc
ident
homolog
human
rhesu
pathogen
genom
rhesu
macaqu
use
studi
fundament
aspect
immunolog
includ
develop
mainten
tcell
memori
immun
domin
age
immun
system
also
mani
studi
immun
respons
rhesu
macaqu
model
human
infect
human
immunodefici
viru
hiv
influenza
viru
tuberculosi
epsteinbarr
viru
ebv
cytomegaloviru
smallpox
measl
sever
acut
respiratori
syndrom
furthermor
rhesu
macaqu
instrument
design
test
vaccin
infect
hiv
smallpox
creat
drug
manag
hivaid
understand
femal
reproduct
cycl
develop
embryo
propag
embryon
stem
cell
genom
rhesu
macaqu
clone
surprisingli
normal
gene
sequenc
healthi
macaqu
caus
profound
diseas
human
exampl
normal
sequenc
phenylalanin
hydroxylas
macaqu
mutat
sequenc
respons
phenylketonuria
human
gene
famili
conserv
evolutionari
pressur
expans
human
macaqu
great
ape
chimpanze
eg
cholesterol
pathway
wherea
uniqu
expans
human
chimpanze
macaqu
eg
major
histocompat
gene
abund
macaqu
rhesu
macaqu
instrument
understand
key
featur
reproduct
howev
male
femal
fertil
month
per
year
season
influenc
geograph
origin
still
observ
sever
year
hous
research
coloni
western
countri
sinc
rhesu
macaqu
longer
avail
india
start
use
less
research
often
consider
lead
time
sourc
anim
addit
progress
replac
cynomolgu
monkey
preclin
toxicolog
studi
part
bigger
size
requir
larg
amount
drug
dose
make
difficult
handl
season
reproduct
make
use
reproduct
development
studi
difficult
result
less
toxicolog
background
data
avail
interpret
find
cynomolgu
monkey
becom
wide
use
primat
speci
preclin
toxicolog
studi
wide
avail
purpos
bred
laboratori
use
size
repres
good
compromis
regard
amount
drug
requir
dose
amount
bloodtissu
sampl
sinc
gener
smaller
rhesu
macaqu
tabl
cynomolgu
macaqu
especi
use
reproduct
development
toxicolog
lower
speci
pharmacolog
relev
given
close
resembl
human
also
good
model
develop
local
administ
drug
use
specif
ocular
diseas
prostat
disord
inhal
nevertheless
although
specif
inform
easili
obtain
numer
breed
coloni
cynomolgu
monkey
extens
character
rhesu
macaqu
term
genom
howev
effort
underway
compar
screen
rhesu
cynomolgu
macaqu
speci
genom
rhesu
cynomolgu
macaqu
speci
exhibit
substanti
variat
depend
origin
genet
background
exampl
chinesederiv
popul
rhesu
macaqu
shown
resist
simian
immunodefici
viru
indianderiv
popul
hematolog
clinic
chemistri
differ
also
demonstr
two
popul
rhesu
macaqu
depend
genet
background
understood
use
guid
research
although
cynomolgu
monkey
commonli
use
develop
biopharmaceut
mab
recombin
protein
rel
littl
inform
genom
public
domain
databas
nevertheless
cynomolgu
monkey
origin
three
differ
popul
eg
indochina
insular
asia
philippin
mauritiu
genet
featur
anim
mauritiu
philippin
exhibit
potenti
lower
genet
divers
even
gene
involv
immun
respons
differ
gene
sequenc
target
protein
encount
within
cynomolgu
monkey
sourc
differ
geograph
origin
eg
china
philippin
mauritiu
rais
concern
certain
genet
variant
might
result
loss
gain
pharmacolog
respons
cynomolgu
monkey
coloni
use
toxicolog
studi
phenotyp
differ
cynomolgu
monkey
divers
geograph
origin
particular
immun
system
function
well
establish
illustr
divers
major
histocompat
complex
mhc
genet
cynomolgu
monkey
differ
geograph
origin
collect
observ
suggest
prospect
assess
target
gene
variat
may
warrant
cynomolgu
monkey
part
nhpspecif
aspect
standard
toxicolog
studi
nhp
speci
pharmacolog
toxicolog
studi
moreov
identifi
sequenc
variat
within
target
gene
requir
complementari
target
expressiondistribut
epitopebind
andor
function
readout
c
jacchu
common
marmoset
one
primit
nhp
speci
use
wide
fundament
biolog
pharmacolog
toxicolog
studi
util
speci
may
provid
optim
compromis
ethic
consider
diseas
understand
drug
develop
scientif
rational
care
consid
use
justifi
sever
advantag
use
marmoset
model
nonclin
develop
pharmaceut
product
number
uniqu
physiolog
differ
old
world
primat
rhesu
cynomolgu
macaqu
new
world
primat
marmoset
exampl
anatom
differ
placent
frequent
twin
lead
bone
marrow
chimer
dizygot
twin
limit
divers
mhc
class
ii
loci
identifi
tamarin
marmoset
may
respons
differ
diseas
suscept
exploit
infecti
diseas
studi
avail
research
tool
limit
past
make
marmoset
less
attract
rhesu
macaqu
anim
model
longer
case
number
key
area
experiment
autoimmun
encephalomyel
eae
wellestablish
anim
model
multipl
sclerosi
ms
diseas
induc
common
marmoset
close
resembl
ms
rodent
primat
model
term
clinic
sign
lesion
evolut
uniqu
particular
marmoset
term
full
bone
marrow
chimer
litterm
key
understand
diseas
pathogenesi
eae
model
use
preclin
evalu
novel
immunotherapi
test
new
antiinflammatori
agent
tolerancebas
therapi
costimul
target
therapi
marmoset
also
use
wide
neurosci
research
program
model
cerebr
vascular
diseas
tardiv
dyskinesia
neurodegen
diseas
studi
normal
neurophysiolog
common
marmoset
use
extens
infecti
diseas
research
larg
part
uniqu
sensit
number
import
human
infecti
agent
includ
viral
bacteri
parasit
agent
particular
marmoset
suscept
varieti
herp
viru
agent
includ
gammaherp
virus
ebv
herpesviru
saimiri
herp
simplex
viru
hepat
viru
infect
junin
viru
malaria
measl
gb
viru
b
surrog
model
human
hepat
c
viru
reason
marmoset
highli
suscept
infect
mani
agent
understood
limit
divers
mhc
class
ii
loci
hypothes
play
role
mention
particular
marmoset
extens
use
investig
molecular
pathogenesi
viralinduc
lymphoma
ebv
lymphocrypto
viru
lcv
model
viral
oncogenesi
viral
persist
marmoset
also
use
nonrod
second
speci
drug
safeti
assess
new
chemic
entiti
nce
recent
biopharmaceut
base
side
effect
find
given
drug
metabol
enzym
receptor
found
similar
human
closer
phylogenet
relationship
human
second
speci
dog
common
marmoset
may
suitabl
certain
type
part
nhpspecif
aspect
standard
toxicolog
studi
pharmacokinet
toxicolog
screen
test
item
biopharmaceut
mechan
action
depend
specif
receptor
epitop
relev
speci
may
restrict
nhp
small
size
common
marmoset
may
repres
addit
advantag
reduc
quantiti
compound
synthes
may
translat
shorter
develop
time
howev
short
statur
sensit
activ
level
may
also
pose
uniqu
challeng
nevertheless
develop
program
canakinumab
marmoset
may
suitabl
speci
addit
marmoset
larg
free
diseas
harm
human
result
speci
use
studi
rang
behavior
studi
reproduct
development
protocol
howev
speci
pose
uniqu
challeng
sensit
small
size
hous
condit
high
activ
level
mani
drug
develop
intend
chronic
administr
infant
women
childbear
potenti
wocbp
fertil
men
infant
requir
evalu
hazard
fertil
andor
earli
develop
offspr
juvenil
toxic
biolog
often
relev
speci
assess
nhp
nce
reproduct
strategi
benefit
standard
wellvalid
studi
design
rodent
rabbit
extens
histor
databas
avail
specif
consider
biopharmaceut
protein
taken
account
freeli
diffus
across
membran
includ
placenta
therefor
expect
affect
earli
stage
develop
especi
embryogenesi
embryofetu
directli
expos
earli
life
although
mab
fc
fusion
protein
also
larg
protein
activ
transport
mother
fetu
mammal
via
neonat
fc
receptor
immunoglobulin
ig
g
fcrn
variabl
efficaci
function
igg
subclass
antibodi
deriv
igg
igg
igg
igg
long
halflif
mani
therapeut
igg
may
result
prolong
pharmacolog
activ
effect
develop
fetu
includ
immun
system
development
immunotox
transfer
antibodi
occur
mainli
second
third
trimest
human
fcrn
start
express
placenta
antibodi
recombin
protein
intact
igg
fc
portion
transport
across
placenta
wherea
antibodi
fragment
fab
dab
scfv
f
ab
without
fc
similar
placent
transfer
igg
demonstr
human
nhp
igg
mab
transfer
fetu
later
pregnanc
organ
develop
end
evalu
effect
therapeut
igg
antibodi
fc
fusion
protein
embryofet
develop
systemat
requir
prior
enrol
wocbp
phase
ii
clinic
trial
nce
accord
revis
ich
guidelin
woman
accident
becam
pregnant
administ
igg
mab
clinic
trial
risk
exposur
develop
offspr
earli
week
pregnanc
low
potenti
advers
effect
fetu
earli
stage
like
due
secondari
effect
matern
toxic
rather
direct
effect
howev
case
fetal
abnorm
without
matern
toxic
report
consid
secondari
alter
placent
function
andor
reduc
fetal
growth
even
direct
inhibit
target
signal
conceptu
rule
report
antireceptor
insulinlik
growth
factor
igfr
therefor
assess
design
base
risk
may
relat
target
modul
mother
infant
care
review
distribut
role
target
differ
physiolog
condit
import
appreci
risk
adapt
studi
design
consequ
standard
studi
design
use
rodent
rabbit
allow
step
reproduct
develop
evalu
describ
gener
predict
provid
therapeut
mab
modul
pathway
physiolog
differ
rodent
rabbit
human
convers
studi
design
use
nhp
cover
aspect
reproduct
eg
direct
fertil
assess
mate
egg
implantationpregn
confirm
day
gestat
may
allow
full
evalu
specif
risk
human
howev
physiolog
reproduct
pregnanc
parturit
includ
hormon
control
close
human
nhp
allow
better
identif
hazard
provid
appropri
studi
design
appli
unlik
rodent
relev
nhp
model
development
toxic
well
establish
spontan
incid
congenit
defect
low
clinic
relev
superior
rodent
demonstr
thalidomid
vitamin
valproic
acid
choos
nhp
assess
effect
therapeut
protein
reproduct
development
function
may
help
identifi
hazard
would
identifi
speci
allow
gener
evalu
clinic
candid
howev
case
relev
nhp
speci
suitabl
assess
reproduct
toxic
clinic
drug
product
case
mab
surrog
use
reproduct
toxic
studi
wellknown
exampl
infliximab
antitumor
necrosi
factor
alpha
efalizumab
eculizumab
respect
among
other
import
consider
choic
nhp
speci
even
substrain
reproduct
development
test
tabl
physiolog
menstrual
cycl
old
world
monkey
close
resembl
human
reason
monkey
speci
belong
group
prefer
experiment
model
studi
human
reproduct
pharmacolog
toxicolog
especi
studi
sex
hormon
synthet
steroid
compound
compound
interfer
hypothalamuspituitaryovarian
testicular
axi
monkey
speci
predict
lack
reproduct
season
conveni
bodi
size
close
resembl
human
physiolog
thank
avail
larg
histor
databas
cynomolgu
monkey
speci
choic
reproduct
toxic
studi
averag
durat
menstrual
cycl
femal
day
endocrinolog
ovarian
cycl
similar
women
one
predomin
follicl
matur
ovul
marker
menstrual
cycl
also
similar
women
cycl
monitor
daili
vagin
smear
also
strong
similar
male
cynomolgu
monkey
men
term
endocrin
control
testicular
function
follicl
stimul
hormon
fsh
especi
part
nhpspecif
aspect
standard
toxicolog
studi
import
spermatogenesi
inhibin
b
import
marker
testicular
toxic
prostat
anatomi
control
prostat
function
fertil
rate
typic
around
preimplant
loss
evalu
relev
period
evalu
advers
drug
effect
organogenesi
take
place
mainli
gestat
day
palat
fusion
occur
around
gestat
day
pregnanc
last
around
day
rang
day
matur
differ
organ
system
evolv
similarli
human
notic
differ
includ
earlier
bone
ossif
respiratori
urinari
system
matur
birth
rapid
matur
digest
system
twin
pregnanc
extrem
rare
macaqu
overal
twin
live
birth
incid
around
low
fertil
rate
high
abort
rate
speci
limit
detect
infrequ
risk
nevertheless
size
eas
hous
extens
panel
reagent
make
attract
model
sever
market
product
test
speci
basiliximab
adalimumab
rituximab
natalizumab
ustekinumab
alefacept
omalizumab
partial
complet
evalu
embryo
fetal
postnat
develop
much
ethic
pressur
limit
use
nhp
especi
reproduct
toxicolog
howev
exampl
rodent
help
hazard
identif
illustr
two
case
direct
solubl
target
inflammatori
indic
develop
cynomolgu
monkey
gener
toxic
studi
unev
potenti
effect
fetu
develop
infant
address
singl
enhanc
pre
postnat
develop
studi
cynomolgu
monkey
decis
base
normal
fertil
reproduct
develop
target
knockout
mice
mice
treat
therapeut
antibodi
block
upstream
signal
receptor
base
unev
embryofet
develop
efd
studi
cynomolgu
monkey
treat
therapeut
antibodi
target
signal
pathway
gestat
day
undergo
cesarean
deliveri
gestat
day
therefor
pregnant
femal
macaqu
administ
weekli
gestat
day
approxim
gestat
day
allow
deliv
offspr
natur
rais
infant
matern
anim
toler
antibodi
treatment
gener
toxic
studi
without
chang
compar
control
anim
deliv
healthi
infant
develop
normal
function
immun
system
howev
increas
incid
treatmentrel
perinat
mortal
observ
infant
macroscop
examin
deced
reveal
skull
bone
luxat
subdur
cerebellar
superfici
brain
hemorrhag
suggest
difficult
deliveri
empti
gastrointestin
tract
indic
absenc
suckl
birth
unexpectedli
treat
matern
anim
experienc
longer
pregnanc
control
mean
day
higher
incid
retain
placenta
prenat
matern
mortal
associ
case
genit
hemorrhag
observ
dystocia
one
lead
caus
late
pregnanc
loss
cynomolgu
monkey
rhesu
monkey
baboon
often
result
intracrani
traumahemorrhag
nonviabl
fetusinf
howev
difficult
deliveri
rare
result
matern
death
usual
associ
import
genit
blood
loss
even
case
placent
retent
care
review
literatur
light
find
studi
suggest
solubl
target
may
inde
play
role
parturit
indic
increas
circul
concentr
target
third
trimest
pregnanc
increas
messeng
rna
protein
concentr
cervix
myometrium
choriodecidua
labor
target
thought
involv
local
process
inflamm
occur
parturit
enabl
recruit
leukocyt
cervix
uterin
wall
induc
cervic
ripen
dilat
probabl
resorpt
interfac
placenta
uterin
wall
also
promot
express
prostaglandin
synthas
cervix
myometrium
choriodecidua
placenta
enabl
effici
contract
although
addit
factor
interf
parturit
rule
inhibit
target
signal
may
explain
observ
matern
anim
matern
mortal
consid
direct
consequ
long
difficult
labor
associ
instanc
hemorrhag
caus
incomplet
resorpt
placentauterin
interfac
genitourinari
infect
result
prolong
labor
perinat
infant
mortal
consid
indirectli
link
treatment
result
head
injuri
parturit
lack
matern
care
first
critic
hour
birth
find
could
observ
mice
whose
physiolog
parturit
differ
monkey
studi
specif
address
parturit
highlight
risk
pregnant
women
still
expos
mab
end
pregnanc
base
similar
physiolog
pregnanc
parturit
nhp
human
exampl
illustr
need
care
evalu
target
express
biolog
target
potenti
role
pregnanc
well
need
understand
close
test
speci
human
pathway
explor
anoth
exampl
cynomolgu
monkey
shown
sensit
rodent
detect
advers
effect
pregnanc
case
solubl
receptor
treatment
pregnant
cynomolgu
monkey
human
solubl
mgkg
intraven
organogenesi
gestat
day
result
increas
incid
spontan
abort
embryofet
death
stillborn
neonat
howev
pregnant
crl
mice
treat
intraven
solubl
mous
surrog
organogenesi
present
advers
effect
equival
dose
mgkg
mice
may
like
possibl
reason
reproduct
effect
seen
mous
studyi
alreadi
bia
tip
way
littl
effect
although
cynomolgu
monkey
establish
nhp
model
reproduct
development
toxicolog
sever
advantag
conduct
development
toxic
studi
use
marmoset
consider
includ
specif
crossreactivityparticularli
biologicsand
specif
teratogen
risk
difficult
demonstr
speci
one
offspr
reproduct
point
view
marmoset
uniqu
among
nhp
differ
human
key
respect
femal
menstrual
bleed
cycl
result
multipl
ovul
postpartum
concept
uncommon
durat
menstrual
cycl
vari
day
long
luteal
phase
midphas
fsh
peak
simultan
matur
one
four
egg
ovarian
cyclic
control
monitor
progesteron
trigger
luteolysi
administ
result
control
efd
studi
feasibl
multipl
simultan
ovul
result
litter
part
nhpspecif
aspect
standard
toxicolog
studi
size
rang
one
four
birth
twin
triplet
frequent
interestingli
marmoset
natur
high
abort
rate
reduc
number
fetus
utero
gener
nurs
two
offspr
compar
old
world
monkey
father
stay
mother
entir
durat
pregnanc
prevent
abort
gestat
last
day
interbirth
interv
approxim
month
concept
occur
day
postpartum
contrast
human
twin
placent
disk
suppli
blood
vessel
fetus
share
anastomos
chorion
commonli
occur
exhibit
hematopoiet
xxxi
chimer
case
twin
opposit
sex
addit
marmoset
chimera
least
two
fertil
egg
earli
embryo
fuse
togeth
differ
phenotyp
may
subtl
hitchhik
thumb
straight
thumb
differ
hair
growth
opposit
side
bodi
etc
complet
undetect
marmoset
new
world
monkey
speci
chorion
gonadotropin
hormon
play
role
lutein
hormon
lh
key
differ
present
male
control
leydig
cell
function
testosteron
product
lh
entir
differ
human
regul
gene
chromosom
differ
male
old
world
monkey
human
key
fertil
gene
eg
daz
absent
consequ
even
organ
testicular
germin
epithelium
similar
man
correspond
function
hormon
spermatogenesi
human
remain
unknown
reproduct
cycl
consider
shorter
macaqu
male
attain
fertil
month
age
review
see
ref
speci
valid
relev
efd
studi
segment
ii
event
cynomolgu
monkey
use
eg
biopharmaceut
pharmacolog
activ
cynomolgu
rhesu
monkey
effect
canakinumab
embryofet
develop
assess
marmoset
use
drug
product
find
associ
canakinumab
treatment
slight
reduct
number
fetus
high
dose
correl
slight
trend
toward
decreas
placent
weight
treatmentrel
effect
fetal
develop
despit
confirm
placent
transfer
igg
time
cesarean
deliveri
gestat
day
given
transfer
igg
across
placenta
start
late
gestat
unlik
fetu
expos
canakinumab
organogenesi
publish
exampl
use
marmoset
reproduct
development
toxicolog
feasibl
marmoset
model
full
rang
development
studi
includ
segment
iii
prepostnat
studi
must
fulli
evalu
high
speci
specif
sequencestructur
immun
receptor
target
mab
make
select
appropri
anim
model
challeng
probabl
less
true
smallmolecul
drug
howev
nhp
commonli
select
anim
model
safeti
assess
immunomodul
given
genet
similar
human
homolog
immun
system
human
reason
practicabilityavail
cynomolgu
monkey
prefer
nhp
speci
although
occasion
marmoset
rhesu
macaqu
use
nevertheless
safetyrelev
function
differ
primat
human
immun
system
despit
close
evolutionari
relationship
includ
exampl
differ
mhc
gene
distribut
function
fc
receptor
tolllik
receptor
sensit
complement
activ
need
consid
assess
safeti
immunomodulatori
compound
specif
agonist
rang
potenti
liabil
associ
immun
agon
may
explor
nhp
cynomolgu
monkey
use
relev
toxicolog
speci
immunostimulatori
agent
tolllik
receptor
agonist
howev
special
recognit
regard
clinic
risk
system
cytokin
releas
certain
target
warrant
nhp
alway
predict
potenti
toxic
human
import
differ
human
nhp
cynomolgu
macaqu
stronger
human
tcell
prolif
respons
upon
activ
via
tcell
receptor
consequ
humanspecif
loss
tcell
siglec
express
later
stage
evolut
siglec
inhibitori
signal
molecul
express
immun
cell
downregul
cellular
activ
pathway
via
cytosol
immunoreceptor
tyrosinebas
inhibitori
motif
concord
speciesrel
differ
siglec
express
observ
sever
common
human
tcellmedi
diseas
bronchial
asthma
rheumatoid
arthriti
type
diabet
report
chimpanze
great
ape
lack
siglec
express
human
may
partial
explain
cytokin
releas
syndrom
cr
human
accur
predict
nhp
rodent
lifethreaten
cytokin
storm
effect
induc
result
unexpect
activ
prolifer
cytokin
releas
effector
memori
cell
predominantli
resid
tissu
effect
observ
cynomolgu
monkey
express
effector
memori
cell
mice
rapid
regulatori
cell
expans
quench
proinflammatori
effect
rel
small
effector
tcell
popul
anim
compar
matur
human
immun
system
humanspecif
differ
tcell
activ
need
care
consid
safeti
assess
immunostimulatori
mab
tcell
target
immun
gene
expand
macaqu
macaqu
genom
major
histocompat
gene
three
time
human
clinic
signific
macaqu
use
experiment
model
human
immun
system
contrast
marmoset
exhibit
limit
divers
mhc
class
ii
loci
fc
receptor
plasma
membran
glycoprotein
bind
fc
region
antibodi
crosslink
fc
receptor
abopson
antigen
complex
initi
cellular
immun
respons
includ
phagocytosi
abdepend
cellmedi
cytotox
respiratori
burst
releas
cytokin
inflammatori
mediat
antigen
present
bind
human
igg
cynomolgu
monkey
broadli
similar
observ
human
howev
import
differ
human
express
monocyt
macrophag
nk
cell
wherea
isoform
express
neutrophil
eosinophil
cell
nhp
one
gene
homolog
human
restrict
nk
cell
monocyt
differ
necessit
test
antihuman
specif
mab
human
transgen
mice
assess
impact
neutrophil
even
greater
differ
fc
receptor
express
distribut
intern
profil
human
mice
also
observ
anatom
differ
human
anim
immun
system
respons
immunomodulatori
drug
review
import
ensur
humanrelev
fc
bind
effector
function
activ
igg
occur
toxicolog
speci
illustr
case
develop
stop
clinic
phase
ii
induc
thromboembol
patient
thromboembol
detect
preclin
studi
conduct
use
cynomolgu
monkey
investig
show
treatment
rhesu
monkey
cynomolgu
monkey
result
thrombi
format
variou
locat
vasculopathi
character
intim
hyperplasia
fulllength
induc
platelet
aggreg
serotonin
releas
bound
target
human
rhesu
monkey
construct
base
fab
fragment
fulllength
antibodi
aglycosyl
fc
caus
platelet
aggreg
activ
vitro
thromboembol
intim
vascular
hyperplasia
vivo
bind
target
compar
affin
mechan
fulli
understood
one
hypothesi
may
play
role
hemostasi
platelet
biolog
function
primari
signal
receptor
serv
dock
molecul
immun
complex
may
drive
transloc
platelet
surfac
enabl
fc
part
antibodi
bound
target
captur
induc
strong
platelet
activ
base
observ
nonclin
develop
new
differ
format
prevent
fc
interact
therefor
conduct
rhesu
monkey
case
studi
also
demonstr
rhesu
monkey
may
toxic
relev
nhp
speci
antibodi
capabl
mediat
complement
activ
bind
contrast
show
littl
complement
activ
show
none
therefor
immunomodulatori
mab
bind
membranebas
target
avoid
cell
deplet
format
silent
reduc
fc
effector
function
often
use
absenc
fc
effector
function
addit
complementdepend
cytotox
intend
pharmacolog
effect
certain
mab
eg
direct
kill
tumor
cell
complement
activ
may
lead
number
safetyrelev
consequ
includ
cytokin
releas
hematolog
effect
andor
potenti
lifethreaten
hemodynam
disturb
despit
larg
concentr
complement
compon
cynomolgu
monkey
serum
compar
human
serum
hemolyt
activ
compar
howev
mechanist
differ
term
cross
speciesspecif
iggfcmedi
complement
activ
particularli
relat
igg
aggreg
statu
exclud
deserv
investig
immunophenotyp
peripher
blood
cell
nhp
readili
avail
varieti
popul
lymphocyt
usual
includ
safeti
assess
immunomodul
standard
panel
includ
total
lymphocyt
helper
lymphocyt
cytotox
lymphocyt
b
lymphocyt
nk
lymphocyt
popul
typic
evalu
unless
warrant
measur
specif
pharmacodynam
respons
may
includ
regulatori
helper
lymphocyt
activ
helper
lymphocyt
activ
cytotox
lymphocyt
effector
memori
helper
lymphocyt
effector
memori
cytotox
lymphocyt
central
memori
helper
lymphocyt
central
memori
cytotox
lymphocyt
helper
lymphocyt
cytotox
lymphocyt
select
assess
driven
biolog
drug
target
consid
part
safeti
assess
casebycas
basi
qualit
quantit
differ
exist
respect
surfac
marker
lymphocyt
relev
studi
immunotox
exampl
marmoset
lack
natur
killer
cell
typic
marker
found
human
convers
cytotox
killer
effector
cell
found
marmoset
found
human
tcelldepend
antigen
respons
tdar
assay
encompass
multipl
aspect
immun
respons
ie
antigen
captur
present
tcell
help
antibodi
format
includ
class
switch
abil
mount
immun
respons
one
end
point
antigenspecif
antibodi
titer
toxicolog
regulatori
guidanc
document
tdar
consid
one
function
assay
choic
evalu
potenti
immunotox
investig
new
drug
howev
interanim
variabl
limit
sensit
assay
studi
power
gener
toxicolog
evalu
despit
similar
behavior
sex
anim
differ
countri
origin
inhibit
tdar
clearli
evidenc
immunosuppress
agent
nhp
demonstr
lack
activ
assay
problemat
definit
biolog
irrelev
variat
establish
keyhol
limpet
hemocyanin
klh
sheep
red
blood
cell
srbc
tetanu
toxoid
tt
commonli
use
antigen
challeng
klh
tt
show
similar
interanim
variabl
trend
less
variabl
srbc
power
analysi
numer
studi
demonstr
anim
group
size
combin
male
femal
could
detect
differ
antiklh
igg
respons
assay
optim
harmon
tdar
nhp
remain
prioriti
function
ex
vivo
assay
nk
cellmedi
lysi
avail
nhp
use
human
myelogen
leukemia
target
cell
line
develop
function
assay
ctl
activ
need
subject
signific
effort
gener
good
concord
pharmacodynam
effect
human
nhp
often
limit
concord
advers
effect
consid
mab
fusion
protein
cell
surfac
target
solubl
target
rare
seriou
advers
event
greater
concern
patient
usual
predict
studi
conduct
normal
healthi
anim
part
reason
anim
studi
fail
detect
effect
nhp
studi
power
detect
rare
event
also
serendipit
infecti
challeng
may
occur
control
laboratori
environ
anim
gener
prescreen
certain
infecti
agent
inclus
studi
anim
test
neg
includ
studi
laboratori
anim
receiv
comed
healthi
enrol
toxicolog
studi
regard
cell
surfac
target
downstream
signal
may
also
differ
antibodi
fusion
protein
test
bind
epitop
nhp
often
relev
speci
develop
biopharmaceut
howev
comprehens
assess
immunotox
remain
challeng
interanim
variabl
associ
certain
paramet
stage
develop
certain
immun
assay
incomplet
knowledg
target
distribut
effector
function
compar
human
greater
understand
background
incid
certain
pathogen
nhp
need
proper
interpret
infecti
agentrel
find
may
misinterpret
treatmentrel
find
result
immunomodul
sever
exampl
demonstr
need
use
nhp
especi
identifi
hazard
reproduct
development
assess
biopharmaceut
nevertheless
import
challeng
may
impact
safeti
risk
assess
human
remain
includ
limit
number
anim
interanim
variabl
associ
paramet
stage
develop
certain
assay
incomplet
knowledg
target
distribut
effector
function
compar
human
differ
inher
speci
use
proven
